The ASX200 hit a 100-day high as Adisyn jumped 17.9% on a graphene milestone, SciDev rose 18.5% on data centre contracts, and Neuren climbed 15.7% on record sales.
Alpha Score of 43 reflects weak overall profile with moderate momentum, weak value, weak quality. Based on 3 of 4 signals — score is capped at 90 until remaining data ingests.
The S&P/ASX 200 hit a new 100-day high Wednesday, adding 15.60 points to 9,161.40. In a session where stock market analysis showed three stocks driving momentum, Adisyn jumped 17.9% after a graphene milestone, SciDev rose 18.5% on data centre contracts, and Neuren Pharmaceuticals climbed 15.7% on record drug sales.
Adisyn (ASX:AI1) said it scaled its low-temperature graphene deposition process to a full 200mm copper semiconductor wafer, completing the deposition below 300°C. The move takes the technology from laboratory samples to an industry-standard format used in chip fabrication. Managing director Arye Kohavi called it a huge step forward. “Scaling a new materials technology from laboratory samples to a full 200mm semiconductor wafer presents significant technical challenges,” he said. The company believes this is the first publicly disclosed demonstration of low-temperature graphene deposition across an entire 200mm wafer. The low temperature is critical because it allows graphene to be added without damaging underlying silicon structures, a hurdle that has kept graphene out of mainstream production. AI1 traded at 16.5¢ as of press time.
SciDev (ASX:SDV) secured its first data centre contracts, covering design, consulting and embedded engineering services for two of Australia’s largest hyperscale operators. The deals are expected to generate roughly $500,000 in revenue during the first half of fiscal 2027, with scope for expansion. CEO Todd Scott said the contracts validate the company’s strategy. “Data centres are becoming increasingly important users of water and are facing growing pressure to improve water efficiency and reduce reliance on potable supply,” he said. SciDev’s capability combines specialist water treatment engineering, modular technology and project delivery experience. The hyperscale sector is under regulatory scrutiny over water usage in drought-prone regions, and the contracts give SciDev a foothold in a market where water demand is expected to grow rapidly as AI compute clusters expand. SDV rose to 16.0¢ in morning trade.
Neuren Pharmaceuticals (ASX:NEU) reported second-quarter 2026 net sales of DAYBUE (trofinetide) at US$125 million, up 30% from the same quarter last year and 24% from the first quarter. Acadia Pharmaceuticals, Neuren's partner, raised its full-year 2026 guidance for DAYBUE to US$480–510 million, from a prior range of US$460–490 million. CEO Jon Pilcher called it the highest quarterly sales since launch. He attributed the growth to the early success of the STIX program in the U.S. and a positive opinion from the European Medicines Agency's CHMP. “Subject to approval being confirmed, we now look forward to Acadia's anticipated European launch later this year,” he said. The 30% year-on-year growth signals strong adoption of the Rett syndrome treatment, and the raised guidance implies confidence in continued momentum. The European launch, if approved, would open a new revenue stream. NEU closed at $21.53.
The ASX200 has gained 1.36% over the last five days and sits 0.56% off its 52-week high. Neuren now awaits the European Commission's decision on the CHMP opinion, which could unlock a market outside the US.
Drafted by a large language model from the source reporting linked above, then screened by automated publishing checks. It is not read by a journalist before publication. Some articles cite our Alpha Score. Verify prices and figures against the original source. Educational coverage, not personalized advice.